<DOC>
	<DOC>NCT01541956</DOC>
	<brief_summary>This is an open-labeled, randomized, multicenter, prospective, parallel group, interventional study to demonstrate the effectiveness of 24 weeks treatment with Vildagliptin 50mg bid as add on to metformin 500 mg bid compared to metformin up to 1000 mg bid in Chinese patients with type 2 diabetes inadequately controlled on sub maximal dosage metformin monotherapy.</brief_summary>
	<brief_title>Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Chinese T2D patients who are inadequate controlled (6.5 %&lt; HbA1C ≤9%) by metformin (≥750mg/d but ≤1000mg/d, ≥12 weeks), Type 1 diabetes and secondary diabetes Acute metabolic diabetic complications within the past 3 months. Acute infections which may influence glucose level. Evidence of significant chronic diabetic complications, Clinically significant renal impairment and hepatic impairment patients, including history of cirrhosis or chronic hepatitis, FPG &gt; 270 mg/dl (15 mmol/l) Any of the following disease within the past 6 months: myocardial infarction (MI); coronary artery bypass surgery or percutaneous coronary intervention; unstable angina or stroke; Congestive heart failure (CHF) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>type 2 diabetes;</keyword>
	<keyword>vildagliptin;</keyword>
	<keyword>metformin;</keyword>
</DOC>